In a study published in The Journal of Molecular Diagnostics in September 2010, miRview® meso was shown to be a highly sensitive test for differentiating mesothelioma from carcinomas in the lung or pleura, with a sensitivity of 100% and a specificity of 94%. View full post on mesothelioma – Bing News
Rosetta Genomics said this week that it has signed an exclusive marketing deal under which tort claims administration firm PACE Claims Services will provide information about Rosetta’s mesothelioma diagnostic test to defendants and insurers in mesothelioma legal cases. View full post on mesothelioma – Yahoo! News Search Results
NEW YORK (GenomeWeb News) – Pace Claims Service will provide educational and marketing services on behalf of Rosetta Genomics for its miRview meso diagnostic test for mesothelioma under an exclusive marketing deal announced today. View full post on mesothelioma – Yahoo! News Search Results
In a study published in The Journal of Molecular Diagnostics in September 2010, miRview® meso was shown to be a highly sensitive test for differentiating mesothelioma from carcinomas in the lung or pleura, with a sensitivity of 100% and a specificity of 94%. View full post on mesothelioma – Bing News
Rosetta Genomics this week unveiled two new microRNA-based tests under development, one a kidney cancer diagnostic and the other a mesothelioma prognosis assay, and disclosed that it will be building up an in-house sales force to market them and certain of its other second-generation products. View full post on Yahoo! News Search Results for mesothelioma
“We are encouraged by the commercial progress we made in the second quarter, with the number of tests performed up more than 170% compared with the immediately preceding quarter. View full post on Yahoo! News Search Results for mesothelioma
Product DescriptionThis digital document is an article from BIOTECH Patent News, published by Thomson Gale on March 1, 2007. The length of the article is 646 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately [...]
Rosetta Genomics this month announced that it has scaled back its work on a serum-based colon cancer-screening assay based on microRNA biomarkers, less than a year after the company said that commercialization of the test, dubbed miRscreen Colon, had become its top priority.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No
